Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services (WST) delivers essential innovations in pharmaceutical packaging and injectable drug delivery systems. This page provides investors and industry professionals with timely updates on the company’s strategic developments, financial performance, and technological advancements.
Access authoritative reporting on WST’s earnings announcements, regulatory milestones, product launches, and global partnerships. Our curated news ensures you stay informed about critical developments in elastomer-based components, biologics containment, and self-injection device platforms.
Explore updates across key areas: quarterly financial results, manufacturing expansions, compliance achievements, and collaborations with healthcare leaders. Content is rigorously verified to support data-driven decisions while adhering to financial disclosure standards.
Bookmark this page for streamlined access to WST’s evolving role in advancing safe, efficient drug delivery solutions worldwide. Check regularly for unbiased insights into one of pharma packaging’s most innovative players.
West Pharmaceutical Services (NYSE: WST) reported its Q1 2023 financial results on April 27, 2023. Net sales were $716.6 million, down 0.5% year-over-year, but organic sales increased by 2.3%. The diluted EPS dropped to $1.85, a decline of 19.2%. The company has raised its full-year net sales guidance to $2.965 billion to $2.990 billion, and adjusted-diluted EPS guidance to $7.50 to $7.65. A dividend of $0.19 per share was approved for Q3 2023, payable on August 2, 2023, to shareholders of record by July 26, 2023. Operational cash flow stood at $138.1 million, reflecting an 8.7% decrease, while free cash flow dropped 34.4% to $56.0 million. The firm anticipates continued growth despite a decline in COVID-19 related sales affecting its Biologics market unit.